4//SEC Filing
Lu Hongbo 4
Accession 0000919574-25-006031
CIK 0001953926other
Filed
Oct 8, 8:00 PM ET
Accepted
Oct 9, 3:37 PM ET
Size
8.4 KB
Accession
0000919574-25-006031
Insider Transaction Report
Form 4
Lu Hongbo
Director
Transactions
- Purchase
Common Stock
2025-10-07$19.00/sh+263,160$5,000,040→ 321,983 total(indirect: See footnote) - Purchase
Common Stock
2024-09-13$17.00/sh+58,823$999,991→ 58,823 total(indirect: See footnote)
Footnotes (3)
- [F1]The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F2]The reported securities are owned directly by NEXTBio Master Fund LP or NextBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NextBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NextBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC.
- [F3](Continued from footnote 2) The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
Zenas BioPharma, Inc.
CIK 0001953926
Entity typeother
Related Parties
1- filerCIK 0001767584
Filing Metadata
- Form type
- 4
- Filed
- Oct 8, 8:00 PM ET
- Accepted
- Oct 9, 3:37 PM ET
- Size
- 8.4 KB